Showing 4391-4400 of 7767 results for "".
- Daily Avena Sativa Skincare Regimen Improves Itch and Dry Skin in Adults Undergoing Systemic Cancer Treatmentshttps://practicaldermatology.com/news/daily-avena-sativa-skincare-regimen-improves-itch-and-dry-skin-in-adults-undergoing-systemic-cancer-treatments-1/2460780/Daily Avena Sativa (Oat) skincare regimen provides a significant improvement in xerosis and pruritus for adult patients undergoing systemic oncology treatments,according to research presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021. "The u
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- San Francisco Dermatologist Bill Kwan Featured in Third Albumhttps://practicaldermatology.com/news/san-francisco-dermatologist-bill-kwan-featured-in-third-album/2460773/As a dermatologist, Bill Kwan, MD plies his craft as the provider of both medical and aesthetic care to patients in San Francisco. As a vocalist, he plies his craft sharing the art of music. Dr. Kwan has released "No Ordinary Love: The Music of Sade." The third album that features Dr. K
- New Studies Support Taltz’s Role in Treating Psoriasishttps://practicaldermatology.com/news/new-studies-support-taltzs-role-in-treating-psoriasis/2460771/Lilly's Taltz delivers more cumulative days with completely clear skin for adults with psoriasis, compared to seven other biologics. What’s more, Taltz also helped patients stay on treatment longer and have more days without additional therapy in three real-world analyses of U
- Dermavant: Posters Unveil Additional Data for Once-Daily Topical Tapinarofhttps://practicaldermatology.com/news/dermavant-posters-unveil-additional-data-for-once-daily-topical-tapinarof/2460770/Dermavant Sciences will present data in poster form from its two pivotal phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, at AAD VMX 2021. Tapinarof is a novel, once-daily therapeutic aryl hydrocarbon recepto
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Int
- Phase 3 Data Show Tolerability, Efficacy for Brickell's Sofpironium Bromide in Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-show-tolerability-efficacy-for-brickells-sofpironium-bromide-in-hyperhidrosis/2460763/Data from the phase 3, open-label, long-term safety study of Brickell Biotech’s sofpironium bromide gel, 5% and 15%, provided clinically meaningful improvement in axillary hyperhidrosis severity as measured by the Hyperhidrosis Disease Severity Measure-
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study
- Favorable 5-Year Data for Janssen’s Tremfya in PsOhttps://practicaldermatology.com/news/favorable-5-year-data-for-janssens-tremfya-in-pso/2460758/Newly presented phase 3 data show that Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years. Treatment impro